Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy almost fully to immune CPI. Still, the majority of patients fail to benefit from CPI treatment, raising the intriguing question on how TIL therapy may fit into the changing landscape of melanoma treatment. We took advantage of data from a unique cohort of patients with MM treated with T-cell therapy in consecutive clinical trials at our institution across the last 10 years. Based on detailed data on patient characteristics, pre-TIL and post-TIL treatments and long-term follow-up, we were able to address the important issue of how TIL therapy can be positioned in the current CPI era. We found that previous progression on anticytotoxic T-lymphocyte-associated protein 4 do not seem to harm neither rate nor duration of response to TIL therapy. Importantly, even in the hard-to-treat population of patients who progressed on antiprogrammed cell death protein 1 (anti-PD-1), an objective response rate of 32% was achieved, including durable responses. Yet, median progression-free survival was reduced in this anti-PD-1 refractory population. Trial registration number: ClinicalTrials.gov ID: NCT00937625, NCT02379195 and NCT02354690.

OriginalsprogEngelsk
TidsskriftJournal for ImmunoTherapy of Cancer
Vol/bind8
Udgave nummer2
ISSN2051-1426
DOI
StatusUdgivet - jul. 2020

Bibliografisk note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 61349773